Mohammed Shurrab
Overview
Explore the profile of Mohammed Shurrab including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Quevillon T, Slade E, Michael F, Benz A, McIntyre W, Parkash R, et al.
Heart Rhythm O2
. 2025 Jan;
5(12):942-950.
PMID: 39803618
Background: There is consensus on the safety of standard dose direct oral anticoagulants (DOACs) for stroke prevention in patients undergoing cardioversion of atrial fibrillation (AF), but outcomes of reduced dose...
2.
Michael F, Quevilllon T, Maisonneuve S, Jackevicius C, Crystal E, Parkash R, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Dec;
PMID: 39719394
Background And Aims: Amiodarone is frequently prescribed alongside direct oral anticoagulants (DOACs) in atrial fibrillation (AF). There are concerns regarding drug-drug interactions (DDIs) between amiodarone and DOACs. The literature is...
3.
Shurrab M, Janmohamed A, Ayala-Paredes F, Sturmer M, Toal S, Sarrazin J, et al.
Heart Rhythm O2
. 2024 Nov;
5(9):668-671.
PMID: 39493910
No abstract available.
4.
Faridi B, Davies S, Narendrula R, Middleton A, Atoui R, McIsaac S, et al.
Eur J Prev Cardiol
. 2024 Oct;
PMID: 39470401
Aims: Patients with cardiac disease living in rural areas may face significant challenges in accessing care and studies suggest that living in rural areas may be associated with worse outcomes....
5.
Shurrab M, Austin P, Jackevicius C, Tu K, Qiu F, Haldenby O, et al.
Heart Rhythm
. 2024 Aug;
PMID: 39154873
Background: Despite many atrial fibrillation (AF) patients being at risk of bleeding, very limited data are available on bleeding rates of different direct oral anticoagulants based on the spectrum of...
6.
Shurrab M, Austin P, Jackevicius C, Tu K, Qiu F, Haldenby O, et al.
Heart Rhythm
. 2024 Jun;
21(12):2397-2406.
PMID: 38878942
Background: There are no clinical trials with a head-to-head comparison between the 2 most commonly used oral anticoagulants (apixaban and rivaroxaban) in patients with atrial fibrillation (AF). The comparative efficacy...
7.
Alnasser S, Cavanagh M, Atoui R, Ali N, Nalla B, McKechnie K, et al.
CJC Open
. 2024 Feb;
6(1):47-53.
PMID: 38313339
Background: Despite advancements in critical care and coronary revascularization, cardiogenic shock (CS) outcomes remain poor. Implementing a shock team and use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) have been associated...
8.
Bittira B, Shurrab M, Santi S, Grieve S, MacDonald D
CJC Open
. 2023 Nov;
5(11):793-797.
PMID: 38020335
Background: Data are limited on long-term outcomes in patients who have undergone a reoperation following failure of a stentless aortic valve. Methods: Between 2006 and 2016, a retrospective analysis was...
9.
Shurrab M, Ko D, Jackevicius C, Tu K, Middleton A, Michael F, et al.
Pharmacoepidemiol Drug Saf
. 2023 May;
32(8):817-831.
PMID: 37144449
Background: Propensity score (PS) methods with two treatment groups (e.g., treated vs. control) is a well-established technique for reducing the effects of confounding in nonrandomized studies. However, researchers are often...
10.
Hanna G, MacDonald D, Bittira B, Horlick E, Ali N, Atoui R, et al.
CJC Open
. 2022 Dec;
4(12):1053-1059.
PMID: 36562010
Background: Early hospital ( < 48 hours) discharge following transcatheter aortic valve implantation (TAVI) is an increasingly adopted practice; however, data on the safety of such an approach among patients...